In today’s briefing:
- China Meidong: Back the Porsche at 20 HKD
- Health And Happiness (H&H) (1112.HK) – High Bankruptcy Risk Together with Gloomy Prospects
- H&H (1112): Difficult Period?
- Yunkang IPO (PHIP): Growth Still Largely Driven by COVID
- Chinese Property Weekly – 6 May 2022 – Lucror Analytics
- Chinese Property Weekly – 6 May 2022 – Lucror Analytics
- Weekly Wrap – 06 May 2022
- Weekly Wrap – 06 May 2022
China Meidong: Back the Porsche at 20 HKD
- China Meidong Auto (1268 HK) trades at a 12x/9x PE FY22/23E with a 6.5% dividend yield at a 20 HKD/share price (assuming an 80% payout ratio).
- In buying China Meidong Auto (1268 HK), you get an industry leader in the dealership space with supreme execution (35% ROE/47% CAGR profit growth/best capital allocator).
- The integration of the Starchase Porsche Dealerships provides an upside potential, as the management, with their superior track record, can significantly improve the target’s operations.
Health And Happiness (H&H) (1112.HK) – High Bankruptcy Risk Together with Gloomy Prospects
- H&H is faced with multiple challenges. Internally, the performance is under pressure, with stagnating revenue, decreasing profits, cash flow shortage and bankruptcy risk.It’s difficult for H&H to turn things around.
- Externally, factors such as the declining birth rate, lower demand, fierce competition in the infant formulas market, rising costs due to inflation, and economic slowdown worsen the Company’s prospects.
- Based on our 2022 forecast (14% or lower adjusted EBITDA margin,1%-2% or flat revenue growth), we do not think H&H is a good investment. We are conservative about its outlook.
H&H (1112): Difficult Period?
- FY 2021 was a difficult period for Health And Happiness (H&H) (1112 HK) with the lower than usual sales growth and a big one-off expenses.
- It is true that the D/E ratio has gone up to 161% but this is not the first time it happened.
- FCF/Sales remain at low double-digit and cash/TA is also at low double-digit so it is far from going bust.
Yunkang IPO (PHIP): Growth Still Largely Driven by COVID
- Yunkang Group (2325 HK) is a medical operation service provider in China and offers a full suite of diagnostic testing services.
- The company’s IPO application has been approved and plans to raise about US$139m. In this insight, we have highlighted some of the key new data points from PHIP filing.
- Revenue grew 8.8% YoY in 2021 excl. Cov-19 tests (vs 80.2% from Cov-19 tests) and we are yet to see major improvements excluding the positive impact on margins from COVID.
Chinese Property Weekly – 6 May 2022 – Lucror Analytics
The Chinese Property Weekly focuses on providing updates in the Chinese real-estate sector, including recent regulatory and company developments, top and bottom performers, rating actions, as well as a list of bond maturities in the next 30 days.
Chinese Property Weekly – 6 May 2022 – Lucror Analytics
The Chinese Property Weekly focuses on providing updates in the Chinese real-estate sector, including recent regulatory and company developments, top and bottom performers, rating actions, as well as a list of bond maturities in the next 30 days.
Weekly Wrap – 06 May 2022
Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.
In this Insight:
- Sunac China Holdings
- Kawasan Industri Jababeka
- Kwg Property Holding
- Tata Steel Ltd
- China Jinmao Holdings
and more…
Weekly Wrap – 06 May 2022
Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.
In this Insight:
- Sunac China Holdings
- Kawasan Industri Jababeka
- Kwg Property Holding
- Tata Steel Ltd
- China Jinmao Holdings
and more…
Before it’s here, it’s on Smartkarma